Implementing an Opioid Risk Assessment Telephone Clinic: Outcomes from a Pharmacist-Led Initiative in a Large Veterans Health Administration Primary Care Clinic, December 15, 2014–March 31, 2015

Jacobs, Sara C.; Son, Elizabeth K.; Tat, Christina; Chiao, Phillip; Dulay, Maya; Ludwig, Alison

doi:10.1080/08897077.2015.1129527

Cited by 33 publications

(48 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…“Implementing an Opioid Risk Assessment Telephone Clinic: Outcomes From a Pharmacist‐Led Initiative in a Large Veterans Health Administration Primary Care Clinic” …”

Section: Resultsmentioning

confidence: 99%

“…Two articles presented programs that successfully decreased the overall amount of opioids prescribed and also increased safe opioid prescribing practices . These interventions mainly focused on a pharmacist reviewing patients charts before a visit or after a refill request.…”

Section: Discussionmentioning

confidence: 99%

“…Studies by Bounthavong et al, Cox et al, and Jacobs et al all represent different interventions that can result in increased naloxone prescribing. Whether general educational outreach or patient‐specific recommendations, these interventions were able to improve identification of patients who would benefit from naloxone and increase the overall amount of naloxone prescribed.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Pharmacists and the opioid crisis: A narrative review of pharmacists' practice roles

Bratberg

Smothers

Collins

et al. 2019

J Am Coll Clin Pharm

View full text Add to dashboard Cite

Introduction Nearly 2.5 million Americans have an opioid use disorder (OUD) related to prescription and/or illicit opioids. Pharmacists, as one of the most accessible care providers, are essential in mitigating the mortality and morbidity of the opioid overdose crisis. Pharmacists are involved in numerous care activities related to this crisis and to caring for patients with an OUD. Objective The objective of this paper was to conduct a literature review to highlight several pharmacist‐driven practices that provide a broad range of prevention, harm reduction, treatment, and recovery services to patients affected or potentially affected by the opioid crisis. Methods Articles had to meet the criteria of describing pharmacist‐led practice related to providing care to patients at risk of an opioid overdose, with an OUD, or related to opioid safety. The literature search was conducted in 2018 and utilized numerous sources including: OneSearch (EBSCOhost), PubMed, ScienceDirect, and the Journal of the American Pharmacists Association Opioid Topic Collection. Results Seven articles were chosen for inclusion in this review. These studies report on innovative programs and practices that describe the role of pharmacists in the opioid crisis. Studies demonstrate the types of involvement pharmacists have in caring for patients throughout the care continuum: actively engaged in upstream interventions aimed at preventing misuse and improve safety; screening and monitoring opioid prescribing and usage; providing access to naloxone; and, assisting in the recovery and rehabilitation process of patients with OUD, including collaboratively managing OUD with evidence‐based pharmacotherapy. Conclusion The studies included in our narrative review demonstrate how innovative programs and practices can expand the role of pharmacists throughout the entire spectrum of interventions applied to the opioid crisis by capitalizing on their existing skill sets and knowledge.

show abstract

“…“Implementing an Opioid Risk Assessment Telephone Clinic: Outcomes From a Pharmacist‐Led Initiative in a Large Veterans Health Administration Primary Care Clinic” …”

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacists and the opioid crisis: A narrative review of pharmacists' practice roles

Bratberg

Smothers

Collins

et al. 2019

J Am Coll Clin Pharm

View full text Add to dashboard Cite

show abstract

“…Chronic prescribing has been defined as 90 days or more of opioid prescribing in the past 120 days; 15 this definition is congruent with that of the International Association for the Study of Pain 6…”

Section: Chronic Pain: Definitions and Epidemiologymentioning

confidence: 99%

Using opioids in general practice for chronic non‐cancer pain: an overview of current evidence

Currow

Phillips²,

Clark

2016

Medical Journal of Australia

View full text Add to dashboard Cite

Chronic non-cancer pain (lasting more than 3 months) is highly prevalent in Australia (17% of males and 20% of females) and its optimal management is crucial to the health and wellbeing of the community. For 5% of the population, such pain interferes markedly with daily function. Part of the treatment for acute non-cancer pain for many people will include opioid analgesics at least for days to weeks. However, as pain becomes chronic, evidence to support ongoing prescription of opioids is lacking. There is increasing pressure to ensure that prescribing opioid analgesics is minimised to reduce not only the risk of dependence and illicit diversion but also the potential harms associated with tolerance, side effects and complications. Frameworks for considering opioid prescribing include assessing suitability of the patient for opioids; initiating a trial of therapy; and monitoring long term use. There is limited evidence of the long term efficacy of opioids for chronic non-cancer pain, and documented clinical consequences beyond addiction include acceleration of loss of bone mineral density, hypogonadism and an association with increased risk of acute myocardial infarction. Careful clinical selection of patients can help optimise the evidence-based use of opioids for chronic non-cancer pain: only treat pain that has been as well defined as possible when non-opioid therapies have not been effective; consider referral to specialist services for assessment if doses are above 100 mg oral morphine equivalent per 24 hours or the duration of therapy is longer than 4 weeks; limit prescribing to only one practitioner; seek an agreement with the patient for the initiation and potential withdrawal of opioids if the therapeutic trial is not effective.

show abstract

“…13 Chronic neuropathic pain is estimated to occur in one in 11 people. 14 Chronic prescribing has been defined as 90 days or more of opioid prescribing in the past 120 days; 15 this definition is congruent with that of the International Association for the Study of Pain. 6 Current guidelines for safe prescribing of opioids for chronic non-malignant pain…”

Section: Chronic Pain: Definitions and Epidemiologymentioning

confidence: 88%

Using opioids in general practice for chronic non‐cancer pain: an overview of current evidence

Currow

Phillips

Clark

2016

Medical Journal of Australia

View full text Add to dashboard Cite

Implementing an Opioid Risk Assessment Telephone Clinic: Outcomes from a Pharmacist-Led Initiative in a Large Veterans Health Administration Primary Care Clinic, December 15, 2014–March 31, 2015

Abstract: A pharmacist-led telephone risk assessment clinic improved adherence to clinical guidelines and changed opioid prescribing practices in more than one third of assessed patients.

Cited by 33 publications

References 5 publications

Pharmacists and the opioid crisis: A narrative review of pharmacists' practice roles

Pharmacists and the opioid crisis: A narrative review of pharmacists' practice roles

Using opioids in general practice for chronic non‐cancer pain: an overview of current evidence

Using opioids in general practice for chronic non‐cancer pain: an overview of current evidence

Contact Info

Product

Resources

About